Acer Therapeutics (ACER)
(Delayed Data from OTC)
$0.66 USD
0.00 (0.00%)
Updated Nov 20, 2023 03:59 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
Acer Therapeutics Inc. [ACER]
Reports for Purchase
Showing records 1 - 20 ( 213 total )
Company: Acer Therapeutics Inc.
Industry: Medical - Drugs
Company: Acer Therapeutics Inc.
Industry: Medical - Drugs
Company: Acer Therapeutics Inc.
Industry: Medical - Drugs
Acquisition by Zevra Therapeutics Announced; Downgrading to Neutral Without PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Acer Therapeutics Inc.
Industry: Medical - Drugs
Company: Acer Therapeutics Inc.
Industry: Medical - Drugs
Downgrading to Neutral from Buy Solely Due to Likely Acquisition By Zevra
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Acer Therapeutics Inc.
Industry: Medical - Drugs
Company: Acer Therapeutics Inc.
Industry: Medical - Drugs
2Q23: OLPRUVA Commercialized, Should Rectify Currently Low Cash Position
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Acer Therapeutics Inc.
Industry: Medical - Drugs
OLPRUVA Average WAC Equates to About $624k Annually Vs. RAVICTI''s $1.25M
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Acer Therapeutics Inc.
Industry: Medical - Drugs
Company: Acer Therapeutics Inc.
Industry: Medical - Drugs
OLPRUVA Commercialization Moving Swiftly - Drug Now Available In Mid-June
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Acer Therapeutics Inc.
Industry: Medical - Drugs
Company: Acer Therapeutics Inc.
Industry: Medical - Drugs
Looking For a Successful Olpruva Launch in Mid-2023; Reiterate Buy and $12 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Acer Therapeutics Inc.
Industry: Medical - Drugs
4Q22: OLPRUVA To Launch In 3Q23, EDSIVO Pivotal Trial To Enroll By YE22
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Acer Therapeutics Inc.
Industry: Medical - Drugs
Company: Acer Therapeutics Inc.
Industry: Medical - Drugs
OLPRUVA Sales to Begin in 2Q23, Recent Physician Survey Supports Uptake
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Acer Therapeutics Inc.
Industry: Medical - Drugs
All Signs Point to Positive Prospects for ACER-001 at the FDA; Reiterate Buy and $12 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Acer Therapeutics Inc.
Industry: Medical - Drugs
3Q22: Highly Likely Positive ACER-001 PDUFA Date in January 2023
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Acer Therapeutics Inc.
Industry: Medical - Drugs
UNC Receives $3M Grant for ACER-801 Investigator-Sponsored Trial in PTSD
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J